Venlafaxine Explained

Verifiedrevid:459442662
Chirality:Racemic mixture
Class:Serotonin–norepinephrine reuptake inhibitor
Pronounce:
Tradename:Effexor, Efexor, Venbysi XR, others
Dailymedid:Venlafaxine
Pregnancy Au:B2
Routes Of Administration:Oral
Atc Prefix:N06
Atc Suffix:AX16
Legal Au:S4
Legal Br:C1
Legal Br Comment:[1]
Legal Ca:Rx-only
Legal Uk:POM
Legal Uk Comment:[2]
Legal Us:Rx-only
Legal Us Comment:[3] [4]
Bioavailability:42±15%
Protein Bound:27±2% (parent compound), 30±12% (active metabolite, desvenlafaxine)
Metabolism:Extensively metabolised by the liver, primarily via CYP2D6[5]
Metabolites:O-desmethylvenlafaxine (ODV), see desvenlafaxine
Elimination Half-Life:5±2 h (parent compound for immediate release preparations), 15±6 h (parent compound for extended release preparations), 11±2 h (active metabolite)
Excretion:Kidney (87%; 5% as unchanged drug; 29% as desvenlafaxine and 53% as other metabolites)
Index2 Label:as HCl
Cas Number:93413-69-5
Cas Number2:99300-78-4
Cas Number3:609345-58-6 -->
Pubchem:5656
Pubchem2:62923
Drugbank:DB00285
Drugbank2:DBSALT000186
Chemspiderid:5454
Chemspiderid2:56641
Unii:GRZ5RCB1QG
Unii2:7D7RX5A8MO
Unii3:1R8EN4W1EG -->
Kegg:D08670
Kegg2:D00821
Chebi:9943
Chebi2:9944
Chembl:637
Chembl2:1201066
Iupac Name:(RS)-1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]cyclohexanol
C:17
H:27
N:1
O:2
Smiles:OC2(C(c1ccc(OC)cc1)CN(C)C)CCCCC2
Stdinchi:1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3
Stdinchikey:PNVNVHUZROJLTJ-UHFFFAOYSA-N

Venlafaxine, sold under the brand name Effexor among others, is an antidepressant medication of the serotonin–norepinephrine reuptake inhibitor (SNRI) class. It is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. Studies have shown that venlafaxine improves post-traumatic stress disorder (PTSD).[6] It may also be used for chronic pain.[7] It is taken orally (swallowed by mouth). It is also available as the salt venlafaxine besylate (venlafaxine benzenesulfonate monohydrate) in an extended-release formulation (Venbysi XR).

Common side effects include loss of appetite, constipation, dry mouth, dizziness, sweating, insomnia, drowsiness and sexual problems. Severe side effects include an increased risk of suicide, mania, and serotonin syndrome. Antidepressant withdrawal syndrome may occur if stopped. There are concerns that use during the later part of pregnancy can harm the baby. How it works is not entirely clear, but it seems to be related to the potentiation of the activity of some neurotransmitters in the brain.

Venlafaxine was approved for medical use in the United States in 1993.[8] It is available as a generic medication.[8] In 2021, it was the 44th most commonly prescribed medication in the United States with more than 15million prescriptions.[9] [10]

Medical uses

Venlafaxine is used primarily for the treatment of depression, general anxiety disorder, social phobia, panic disorder, and vasomotor symptoms.[11]

Venlafaxine has been used off label for the treatment of diabetic neuropathy[12] and migraine prevention.[13] It may work on pain via effects on the opioid receptor.[14] It has also been found to reduce the severity of 'hot flashes' in menopausal women and men on hormonal therapy for the treatment of prostate cancer.[15] [16]

Due to its action on both the serotoninergic and adrenergic systems, venlafaxine is also used as a treatment to reduce episodes of cataplexy, a form of muscle weakness, in patients with the sleep disorder narcolepsy.[17] Some open-label and three double-blind studies have suggested the efficacy of venlafaxine in the treatment of attention deficit-hyperactivity disorder (ADHD).[18] Clinical trials have found possible efficacy in those with post-traumatic stress disorder (PTSD).[19] Case reports, open trials and blinded comparisons with established medications have suggested the efficacy of venlafaxine in the treatment of obsessive–compulsive disorder.[20]

Depression

A comparative meta-analysis of 21 major antidepressants found that venlafaxine, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, and vortioxetine were more effective than other antidepressants, although the quality of many comparisons was assessed as low or very low.[21] [22]

Venlafaxine was similar in efficacy to the atypical antidepressant bupropion; however, the remission rate was lower for venlafaxine.[23] In a double-blind study, patients who did not respond to an SSRI were switched to either venlafaxine or another SSRI (citalopram); similar improvement was observed in both groups.[24]

Studies have not established its efficacy for use by children.[25] In children and adolescents with depression, venlafaxine increases the risk of suicidal thoughts or attempts.[26] [27] [28] [29] [30] [31]

Higher doses (e.g. 225 mg and 375 mg per day) of venlafaxine are more effective than lower doses (e.g. 75 mg per day), but also cause more side effects.[32]

Studies have shown that the extended release is superior to the immediate release form of venlafaxine.

A meta-analysis has shown that efficacy of venlafaxine is not correlated with baseline severity of depression. In other words, regardless of how severe a person's depression is initially, the efficacy of venlafaxine remains consistent and is not influenced by the severity of depression at the start of treatment.

Contraindications

Venlafaxine is not recommended in patients hypersensitive to it, nor should it be taken by anyone who is allergic to the inactive ingredients, which include gelatin, cellulose, ethylcellulose, iron oxide, titanium dioxide and hypromellose. It should not be used in conjunction with a monoamine oxidase inhibitor (MAOI), as it can cause potentially fatal serotonin syndrome.[33] [34] Venlafaxine might interact with tramadol or other opioids, trazodone, so caution is needed while mixing multiple serotonergic agents together.[35]

Adverse effects

See also: List of adverse effects of venlafaxine.

Venlafaxine can increase eye pressure, so those with glaucoma may require more frequent eye checks.

A 2017 meta-analysis estimated venlafaxine discontinuation rate due to adverse effects to 9.4%.[36]

Suicide

The US Food and Drug Administration (FDA) requires all antidepressants, including venlafaxine, to carry a black box warning with a generic warning about a possible suicide risk.

A 2014 meta analysis of 21 clinical trials of venlafaxine for the treatment of depression in adults found that compared to placebo, venlafaxine reduced the risk of suicidal thoughts and behavior.[37]

A study conducted in Finland followed more than 15,000 patients for 3.4 years. Venlafaxine increased suicide risk by 60% (statistically significant), as compared to no treatment. At the same time, fluoxetine (Prozac) halved the suicide risk.[38]

In a study sponsored by Wyeth, which produces and markets venlafaxine, the data on more than 200,000 cases were obtained from the UK general practice research database. At baseline, patients prescribed venlafaxine had a greater number of risk factors for suicide (such as prior suicide attempts) than patients treated with other anti-depressants. The patients taking venlafaxine had significantly higher risk of suicide than the ones on fluoxetine or citalopram (Celexa). After adjusting for known risk factors, venlafaxine was associated with an increased risk of suicide relative to fluoxetine and dothiepin that was not statistically significant. A statistically significant greater risk for attempted suicide remained after adjustment, but the authors concluded that it could be due to residual confounding.[39]

An analysis of clinical trials by the FDA statisticians showed the incidence of suicidal behaviour among the adults on venlafaxine to be not significantly different from fluoxetine or placebo.[40]

Venlafaxine is contraindicated in children, adolescents and young adults. In children and adolescents with depression, venlafaxine increases the risk of suicidal thoughts or attempts.

Serotonin syndrome

The development of a potentially life-threatening serotonin syndrome (also classified as "serotonin toxicity")[41] may occur with venlafaxine treatment, particularly with concomitant use of serotonergic drugs, including but not limited to SSRIs and SNRIs, many hallucinogens such as tryptamines and phenethylamines (e.g., LSD/LSA, DMT, MDMA, mescaline), dextromethorphan (DXM), tramadol, tapentadol, pethidine (meperidine) and triptans and with drugs that impair metabolism of serotonin (including MAOIs). Serotonin syndrome symptoms may include mental status changes (e.g. agitation, hallucinations, coma), autonomic instability (e.g. tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g. hyperreflexia, incoordination), or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhea). Venlafaxine-induced serotonin syndrome has also been reported when venlafaxine has been taken in isolation in overdose.[42] An abortive serotonin syndrome state, in which some but not all of the symptoms of the full serotonin syndrome are present, has been reported with venlafaxine at mid-range dosages (150 mg per day).[43] A case of a patient with serotonin syndrome induced by low-dose venlafaxine (37.5 mg per day) has also been reported.[44]

Pregnancy

There are few well-controlled studies of venlafaxine in pregnant women. A study released in May 2010 by the Canadian Medical Association Journal suggests use of venlafaxine doubles the risk of miscarriage.[45] [46] Consequently, venlafaxine should only be used during pregnancy if clearly needed. A large case-control study done as part of the National Birth Defects Prevention Study and published in 2012 found a significant association of venlafaxine use during pregnancy and several birth defects including anencephaly, cleft palate, septal heart defects and coarctation of the aorta.[47] Prospective studies have not shown any statistically significant congenital malformations.[48] There have, however, been some reports of self-limiting effects on newborn infants.[49] As with other serotonin reuptake inhibitors (SRIs), these effects are generally short-lived, lasting only 3 to 5 days,[50] and rarely resulting in severe complications.[51]

Bipolar disorder

According to the ISBD Task Force report on antidepressant use in bipolar disorder,[52] during the course of treatment for depression with those suffering from bipolar I and II, venlafaxine "appears to carry a particularly high risk of inducing pathologically elevated states of mood and behavior." Because venlafaxine appears to be more likely than SSRIs and bupropion to induce mania and mixed episodes in these patients, provider discretion is advised through "carefully evaluating individual clinical cases and circumstances."

Liver injury

A rare but serious side effect of venlafaxine is liver injury. It appears to affect both male and female patients with a median age of 44. Cessation of venlafaxine is one of the appropriate measures of management. While the mechanism of venlafaxine-related liver injury remains unclear, findings suggest that it may be related to a CYP2D6 polymorphism.[53]

Overdose

Most patients overdosing with venlafaxine develop only mild symptoms. Plasma venlafaxine concentrations in overdose survivors have ranged from 6 to 24 mg/L, while postmortem blood levels in fatalities are often in the 10–90 mg/L range.[54] Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcome compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Healthcare professionals are advised to prescribe Effexor and Effexor XR in the smallest quantity of capsules consistent with good patient management to reduce the risk of overdose.[55] It is usually reserved as a second-line treatment for depression due to a combination of its superior efficacy to the first-line treatments like fluoxetine, paroxetine and citalopram and greater frequency of side effects like nausea, headache, insomnia, drowsiness, dry mouth, constipation, sexual dysfunction, sweating and nervousness.[56]

There is no specific antidote for venlafaxine, and management is generally supportive, providing treatment for the immediate symptoms. Administration of activated charcoal can prevent absorption of the drug. Monitoring of cardiac rhythm and vital signs is indicated. Seizures are managed with benzodiazepines or other anticonvulsants. Forced diuresis, hemodialysis, exchange transfusion, or hemoperfusion are unlikely to be of benefit in hastening the removal of venlafaxine, due to the drug's high volume of distribution.[57]

Withdrawal syndrome

See main article: Antidepressant withdrawal syndrome.

People stopping venlafaxine commonly experience SSRI withdrawal symptoms such as dysphoria, headaches, nausea, irritability, emotional lability, sensation of electric shocks (commonly called "brain zaps"[58] [59]), and sleep disturbance.[60] Venlafaxine has a higher rate of moderate to severe withdrawal symptoms relative to other antidepressants (similar to the SSRI paroxetine).[61]

The higher risk and increased severity of withdrawal symptoms relative to other antidepressants may be related to the short half-life of venlafaxine and its active metabolite.[62] After stopping venlafaxine, the levels of both serotonin and norepinephrine decrease, leading to the hypothesis that the withdrawal symptoms could result from an overly rapid reduction of neurotransmitter levels.[63]

Other

In rare cases, drug-induced akathisia can occur after use in some people.[64]

Venlafaxine should be used with caution in hypertensive patients. Venlafaxine must be discontinued if significant hypertension persists.[65] [66] [67] It can also have undesirable cardiovascular effects.[68]

Pharmacology

TransporterKi [nM][69] IC50 [nM][70]
SERT8227
NET2480535
DAT7647
Receptor Ki [nM] [71] [72] Species
2230 Human
2004 Human
2792 Human
>1000 Human

Pharmacodynamics

Venlafaxine is usually categorized as a serotonin-norepinephrine reuptake inhibitor (SNRI), but it has also been referred to as a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).[73] It is described as 'synthetic phenethylamine bicyclic derivative with antidepressant activity'.[74] [75] It works by blocking the transporter "reuptake" proteins for key neurotransmitters affecting mood, thereby leaving more active neurotransmitters in the synapse. The neurotransmitters affected are serotonin and norepinephrine. Additionally, in high doses it weakly inhibits the reuptake of dopamine.[76] The frontal cortex largely lacks dopamine transporters; therefore venlafaxine can increase dopamine neurotransmission in this part of the brain.[77] [78]

Venlafaxine selectively inhibits the serotonin transporter at lower doses, but at a dose of 225 mg per day it additionally blocks the norepinephrine transporter (NET), as measured by the intravenous tyramine pressor test.[79]

Venlafaxine indirectly affects opioid receptors as well as the α2-adrenergic receptor, and was shown to increase pain threshold in mice. These benefits with respect to pain were reversed with naloxone, an opioid antagonist, thus supporting an opioid mechanism.[80] [81]

Pharmacokinetics

Venlafaxine is well absorbed, with at least 92% of an oral dose being absorbed into systemic circulation. It is extensively metabolized in the liver via the CYP2D6 isoenzyme to desvenlafaxine (O-desmethylvenlafaxine, now marketed as a separate medication named Pristiq[82]), which is just as potent an SNRI as the parent compound, meaning that the differences in metabolism between extensive and poor metabolisers are not clinically important in terms of efficacy. Side effects, however, are reported to be more severe in CYP2D6 poor metabolisers.[83] [84] Steady-state concentrations of venlafaxine and its metabolite are attained in the blood within 3 days. Therapeutic effects are usually achieved within 3 to 4 weeks. No accumulation of venlafaxine has been observed during chronic administration in healthy subjects. The primary route of excretion of venlafaxine and its metabolites is via the kidneys. The half-life of venlafaxine is relatively short, so patients are directed to adhere to a strict medication routine, avoiding missing a dose. Even a single missed dose can result in withdrawal symptoms.[85]

Venlafaxine is a substrate of P-glycoprotein (P-gp), which pumps it out of the brain. The gene encoding P-gp, ABCB1, has the SNP rs2032583, with alleles C and T. The majority of people (about 70% of Europeans and 90% of East Asians) have the TT variant.[86] A 2007 study[87] found that carriers of at least one C allele (variant CC or CT) are 7.72 times more likely than non-carriers to achieve remission after 4 weeks of treatment with amitriptyline, citalopram, paroxetine or venlafaxine (all P-gp substrates). The study included patients with mood disorders other than major depression, such as bipolar II; the ratio is 9.4 if these other disorders are excluded. At the 6-week mark, 75% of C-carriers had remitted, compared to only 38% of non-carriers.

Chemistry

The IUPAC name of venlafaxine is 1-[2-(dimethylamino)-1-(4 methoxyphenyl)ethyl]cyclohexanol, though it is sometimes referred to as (±)-1-[a-[a-(dimethylamino)methyl]-p-methoxybenzyl]cyclohexanol. It consists of two enantiomers present in equal quantities (termed a racemic mixture), both of which have the empirical formula of C17H27NO2. It is usually sold as a mixture of the respective hydrochloride salts, (R/S)-1-[2-(dimethylamino)-1-(4 methoxyphenyl)ethyl]cyclohexanol hydrochloride, C17H28ClNO2, which is a white to off-white crystalline solid. Venlafaxine is structurally and pharmacologically related to the atypical opioid analgesic tramadol, and more distantly to the newly released opioid tapentadol, but not to any of the conventional antidepressant drugs, including tricyclic antidepressants, SSRIs, MAOIs, or RIMAs.[88]

Venlafaxine extended release is chemically the same as normal venlafaxine. The extended release (controlled release) version distributes the release of the drug into the gastrointestinal tract over a longer period than normal venlafaxine. This results in a lower peak plasma concentration. Studies have shown that the extended release formula has a lower incidence of nausea as a side effect, resulting in better compliance.[89]

Interactions

Venlafaxine should be taken with caution when using St John's wort.[90] Venlafaxine may lower the seizure threshold, and coadministration with other drugs that lower the seizure threshold such as bupropion and tramadol should be done with caution and at low doses.[91]

Society and culture

Recreational use

Venlafaxine can be abused as recreational drug, with damages that can manifest within a month.[92] Hard data regarding prevalence of abuse are not easy to find. Abusers reported usage of extremely high dosage, 5 to 10 times of acceptable clinical dosage. The adverse side effects were strong cases of the listed side effects. As standard measure treatment is to be supervised by a doctor with relevant education, such as neurologist or psychiatrist.

Brand names

Venlafaxine was originally marketed as Effexor in most of the world; generic venlafaxine has been available since around 2008 and extended release venlafaxine has been available since around 2010.[93]

As of January 2020, venlafaxine is marketed under many brand names worldwide, many with alternative extended release forms (not shown): Adefaxin, Alenthus, Altven, Alventa, Amfax, Anapresin, Ansifix, Arafaxina, Argofan, Arrow Venlafaxine, Axone, Axyven, Benolaxe, Blossom, Calmdown, Dalium, Defaxine, Depefex, Depretaxer, Deprevix, Deprexor, Deprixol, Depurol, Desinax, Dislaven, Dobupal, Duofaxin, Easyfor, Ectien, Eduxon, Efastad, Efaxin, Efaxine, Efectin, Efegen, Efevelon, Efevelone, Efexiva, Efexor, Effegad, Effexine, Effexor, Elafax, Elaxine, Elify, Enpress, Enlafax, Envelaf, Falven, Faxigen, Faxine, Faxiprol, Faxiven, Faxolet, Flavix, Flaxen, Fobiless, Ganavax, Idixor, Idoxen, Intefred, Illovex, Lafactin, Lafaxin, Lanvexin, Laroxin, Levest, Limbic, Linexel, Maxibral, Mazda, Melocin, Memomax, Mezine, Neoxacina, Neoxacina, Nervix, Norafexine, Norezor, Norpilen, Noviser, Nulev, Odiven, Olwexya, Oriven, Paxifar, Politid, Pracet, Prefaxine, Psiseven, Quilarex, Rafax, Senexon, Sentidol, Sentosa, Serosmine, Seroxine, Sesaren, Subelan, Sulinex, Sunveniz, Sunvex, Symfaxin, Tedema, Tifaxin, Tonpular, Trevilor, Tudor, Vafexin, Valosine, Vandral, Velaf, Velafax, Velahibin, Velaxin, Velaxor, Velept, Velpine, Venax, Venaxin, Venaxx, Vencarm, Vencontrol, Vendep, Venegis, Venex, Venexor, Venfalex, Venfax, Ven-Fax, Venfaxine, Venforin, Venforspine, Veniba, Veniz, Venjoy, Venla, Venlabax, Venlablue, Venlabrain, Venladep, Venladex, Venladoz, Venlaf, Venlafab, Venlafaxin, Venlafaxina, Venlafaxine, Venlagamma, Venlalic, Venlamax, Venlamylan, Venlaneo, Venlapine, Venla-Q, Venlasand, Venlatrin, Venlavitae, Venlax, Venlaxin, Venlaxine, Venlaxor, Venlazid, Venlectine, Venlifax, Venlift, Venlix, Venlobax, Venlofex, Venlor, Venorion, Venozap, Vensate, Ventab, Venxin, Venxor, Vextor, Venzip, Vexamode, Vfax, Viepax, ViePax, Voxafen, Zacalen, Zanfexa, Zaredrop, Zarelis, Zarelix, and Zenexor.[94]

In some countries, Effexor is marketed by Viatris after Upjohn was spun off from Pfizer.[95] [96]

Veterinary uses

Veterinary overdose in dogs is very well treated by Cyproheptadine HCl.[97]

Venlafaxine is highly toxic to Bacillariophyta and Chlorophyta phytoplankton.[98] Cats are drawn to the smell of venlafaxine and tend to ingest the pills, which is highly toxic to them.[99]

Further reading

Notes and References

  1. Web site: Anvisa . Brazilian Health Regulatory Agency . 31 March 2023 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 3 August 2023 . 16 August 2023 . . pt-BR . 4 April 2023.
  2. Web site: Efexor XL 75 mg hard prolonged release capsules - Summary of Product Characteristics (SmPC) . (emc) . 16 March 2020 . 15 April 2020 . 7 October 2020 . https://web.archive.org/web/20201007180409/https://www.medicines.org.uk/emc/product/5474/smpc . live .
  3. Web site: Effexor XR- venlafaxine hydrochloride capsule, extended release . DailyMed . 11 May 2021 . 12 May 2021 . https://web.archive.org/web/20210512072156/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53c3e7ac-1852-4d70-d2b6-4fca819acf26 . live .
  4. Web site: Venlafaxine tablet, extended release . DailyMed . 30 June 2022 . 7 January 2023.
  5. Book: Dean L . Venlafaxine Therapy and CYP2D6 Genotype . 2015 . National Center for Biotechnology Information (US) . 28520361 . 28 December 2018 . 29 November 2017 . https://web.archive.org/web/20171129181900/https://www.ncbi.nlm.nih.gov/books/NBK305561/#:~:text=Venlafaxine%20is%20metabolized%20into%20its,reduced%20or%20absent%20CYP2D6%20activity. . live . Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, Malheiro AJ .
  6. Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update . Forman-Hoffman V, Middleton JC, Feltner C, Gaynes BN, Weber RP, Bann C, Viswanathan M, Lohr KN, Baker C, Green J . 17 May 2018 . Agency for Healthcare Research and Quality (AHRQ) . 10.23970/ahrqepccer207 . 4 March 2024 . 30204376 . free . 29 July 2023 . 10 July 2018 . https://web.archive.org/web/20180710011511/https://effectivehealthcare.ahrq.gov/topics/ptsd-adult-treatment-update/research-2018 . dead .
  7. Web site: Antidepressants: Another weapon against chronic pain . Mayo Clinic . 25 January 2020 . 26 October 2021 . https://web.archive.org/web/20211026225927/https://www.mayoclinic.org/pain-medications/art-20045647 . live .
  8. Web site: Venlafaxine Hydrochloride Monograph for Professionals . Drugs.com . AHFS . 24 December 2018 . 27 November 2020 . https://web.archive.org/web/20201127001402/https://www.drugs.com/monograph/venlafaxine-hydrochloride.html . live .
  9. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  10. Web site: Venlafaxine - Drug Usage Statistics . ClinCalc . 14 January 2024 .
  11. Web site: venlafaxine-hydrochloride . The American Society of Health-System Pharmacists . 3 April 2011 . 27 November 2020 . https://web.archive.org/web/20201127001402/https://www.drugs.com/monograph/venlafaxine-hydrochloride.html . live .
  12. Grothe DR, Scheckner B, Albano D . Treatment of pain syndromes with venlafaxine . Pharmacotherapy . 24 . 5 . 621–629 . May 2004 . 15162896 . 10.1592/phco.24.6.621.34748 . 28187627 . free .
  13. Book: https://www.ncbi.nlm.nih.gov/books/NBK535363 . 30570984 . 2022 . Singh D, Saadabadi A . Venlafaxine . StatPearls . Treasure Island (FL) . StatPearls Publishing .
  14. Book: The Opioid System as the Interface between the Brain's Cognitive and Motivational Systems . 2018 . Academic Press . 978-0-444-64168-7 . 73 . 9 May 2020 . 27 August 2021 . https://web.archive.org/web/20210827181238/https://books.google.com/books?id=sEFyDwAAQBAJ&pg=PA73 . live .
  15. Web site: Mayo Clinic staff . 2005 . Beyond hormone therapy: Other medicines may help . Hot flashes: Ease the discomfort of menopause . Mayo Clinic . 19 August 2005 . 25 February 2005 . https://web.archive.org/web/20050225032733/http://www.mayoclinic.com/invoke.cfm?id=HQ01409 . live .
  16. Schober CE, Ansani NT . Venlafaxine hydrochloride for the treatment of hot flashes . The Annals of Pharmacotherapy . 37 . 11 . 1703–1707 . November 2003 . 14565812 . 10.1345/aph.1C483 . 45334784 .
  17. Web site: Medications . Stanford University School of Medicine, Center for Narcolepsy . 7 February 2003 . 3 September 2007 . https://web.archive.org/web/20070821090305/http://med.stanford.edu/school/Psychiatry/narcolepsy/medications.html . 21 August 2007 . dead .
  18. Ghanizadeh A, Freeman RD, Berk M . Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: a systematic review of non-controlled and controlled trials . Reviews on Recent Clinical Trials . 8 . 1 . 2–8 . March 2013 . 23157376 . 10.2174/1574887111308010002 .
  19. Pae CU, Lim HK, Ajwani N, Lee C, Patkar AA . Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder . Expert Review of Neurotherapeutics . 7 . 6 . 603–615 . June 2007 . 17563244 . 10.1586/14737175.7.6.603 . 25215502 .
  20. Phelps NJ, Cates ME . The role of venlafaxine in the treatment of obsessive-compulsive disorder . The Annals of Pharmacotherapy . 39 . 1 . 136–140 . January 2005 . 15585743 . 10.1345/aph.1E362 . 30973410 .
  21. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C . Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis . Lancet . 373 . 9665 . 746–758 . February 2009 . 19185342 . 10.1016/S0140-6736(09)60046-5 . 35858125 .
  22. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JP, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JP, Geddes JR . Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis . Lancet . 391 . 10128 . 1357–1366 . April 2018 . 29477251 . 5889788 . 10.1016/S0140-6736(17)32802-7 .
  23. Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA . A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability . Journal of Clinical Psychopharmacology . 26 . 5 . 482–488 . October 2006 . 16974189 . 10.1097/01.jcp.0000239790.83707.ab . 276619 .
  24. Lenox-Smith AJ, Jiang Q . Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor . International Clinical Psychopharmacology . 23 . 3 . 113–119 . May 2008 . 18408525 . 10.1097/YIC.0b013e3282f424c2 . 34986490 .
  25. Courtney DB . Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials . Canadian Journal of Psychiatry . 49 . 8 . 557–563 . August 2004 . 15453105 . 10.1177/070674370404900807 . free .
  26. 3 November 2022 . Antidepressants for children and teenagers: what works for anxiety and depression? . NIHR Evidence . Plain English summary . en . National Institute for Health and Care Research . 10.3310/nihrevidence_53342. 253347210 .
  27. Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, Li X, Cuijpers P, Coghill D, Xiang Y, Hetrick SE, Leucht S, Qin M, Barth J, Ravindran AV, Yang L, Curry J, Fan L, Silva SG, Cipriani A, Xie P . Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis . The Lancet. Psychiatry . 7 . 7 . 581–601 . July 2020 . 32563306 . 7303954 . 10.1016/S2215-0366(20)30137-1 .
  28. Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB, Cox GR, Merry SN, Meader N . New generation antidepressants for depression in children and adolescents: a network meta-analysis . The Cochrane Database of Systematic Reviews . 2021 . 5 . CD013674 . May 2021 . 34029378 . 8143444 . 10.1002/14651858.CD013674.pub2 . Cochrane Common Mental Disorders Group .
  29. Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, Krinitski D, Fusar-Poli P, Correll CU . Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects . World Psychiatry . 19 . 2 . 214–232 . June 2020 . 32394557 . 7215080 . 10.1002/wps.20765 .
  30. Boaden K, Tomlinson A, Cortese S, Cipriani A . Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment . Frontiers in Psychiatry . 11 . 717 . 2 September 2020 . 32982805 . 7493620 . 10.3389/fpsyt.2020.00717 . free .
  31. Correll CU, Cortese S, Croatto G, Monaco F, Krinitski D, Arrondo G, Ostinelli EG, Zangani C, Fornaro M, Estradé A, Fusar-Poli P, Carvalho AF, Solmi M . Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review . World Psychiatry . 20 . 2 . 244–275 . June 2021 . 34002501 . 8129843 . 10.1002/wps.20881 .
  32. Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT . A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression . The Journal of Clinical Psychiatry . 59 . 3 . 116–122 . March 1998 . 9541154 . 10.4088/jcp.v59n0305 .
  33. Web site: Efexor-XR (venlafaxine hydrochloride) . TGA eBS . 11 May 2021 . PDF . 12 May 2021 . https://web.archive.org/web/20210512121509/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04889-3 . live .
  34. Book: The Maudsley Prescribing Guidelines in Psychiatry . Taylor D, Paton C, Kapur S . illustrated . John Wiley & Sons . 2012 . 978-0-470-97948-8.
  35. Ripple MG, Pestaner JP, Levine BS, Smialek JE . Lethal combination of tramadol and multiple drugs affecting serotonin . The American Journal of Forensic Medicine and Pathology . 21 . 4 . 370–374 . December 2000 . 11111800 . 10.1097/00000433-200012000-00015 . 6 April 2022 . live . https://web.archive.org/web/20220406120319/https://pubmed.ncbi.nlm.nih.gov/11111800/ . 6 April 2022 .
  36. Thase M, Asami Y, Wajsbrot D, Dorries K, Boucher M, Pappadopulos E . A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder . Current Medical Research and Opinion . 33 . 2 . 317–326 . February 2017 . 27794623 . 10.1080/03007995.2016.1255185 . Informa UK Limited . 4394404 .
  37. Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ . Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine . Archives of General Psychiatry . 69 . 6 . 580–587 . June 2012 . 22309973 . 3367101 . 10.1001/archgenpsychiatry.2011.2048 .
  38. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J . Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort . Archives of General Psychiatry . 63 . 12 . 1358–1367 . December 2006 . 17146010 . 10.1001/archpsyc.63.12.1358 . free .
  39. Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E . Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study . BMJ . 334 . 7587 . 242 . February 2007 . 17164297 . 1790752 . 10.1136/bmj.39041.445104.BE .
  40. Web site: Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee . 20 June 2007 . 16 November 2006 . Food and Drug Administration: Center for Drug Evaluation and Research . https://web.archive.org/web/20070316092329/https://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf . 16 March 2007 . live.
  41. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM . The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity . QJM . 96 . 9 . 635–642 . September 2003 . 12925718 . 10.1093/qjmed/hcg109 . free .
  42. Kolecki P . Isolated venlafaxine-induced serotonin syndrome . The Journal of Emergency Medicine . 15 . 4 . 491–493 . July–August 1997 . 9279702 . 10.1016/S0736-4679(97)00078-4 .
  43. Web site: Hallucinations as a side effect of venlafaxine treatment . 17 June 2008 . Ebert D, etal . Psychiatry On-line . 21 May 2008 . https://web.archive.org/web/20080521183032/http://www.priory.com/psych/venhall.htm . live .
  44. Pan JJ, Shen WW . Serotonin syndrome induced by low-dose venlafaxine . The Annals of Pharmacotherapy . 37 . 2 . 209–211 . February 2003 . 12549949 . 10.1345/aph.1C021 .
  45. Broy P, Bérard A . Gestational exposure to antidepressants and the risk of spontaneous abortion: a review . Current Drug Delivery . 7 . 1 . 76–92 . January 2010 . 19863482 . 10.2174/156720110790396508 . 28153571 .
  46. Nakhai-Pour HR, Broy P, Bérard A . Use of antidepressants during pregnancy and the risk of spontaneous abortion . CMAJ . 182 . 10 . 1031–1037 . July 2010 . 20513781 . 2900326 . 10.1503/cmaj.091208 .
  47. Polen KN, Rasmussen SA, Riehle-Colarusso T, Reefhuis J . Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007 . Birth Defects Research. Part A, Clinical and Molecular Teratology . 97 . 1 . 28–35 . January 2013 . 23281074 . 4484721 . 10.1002/bdra.23096 .
  48. Gentile S . The safety of newer antidepressants in pregnancy and breastfeeding . Drug Safety . 28 . 2 . 137–152 . 2005 . 15691224 . 10.2165/00002018-200528020-00005 . 24798891 .
  49. de Moor RA, Mourad L, ter Haar J, Egberts AC . [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy] . Nederlands Tijdschrift voor Geneeskunde . 147 . 28 . 1370–1372 . July 2003 . 12892015 .
  50. Ferreira E, Carceller AM, Agogué C, Martin BZ, St-André M, Francoeur D, Bérard A . Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates . Pediatrics . 119 . 1 . 52–59 . January 2007 . 17200271 . 10.1542/peds.2006-2133 . 27443298 .
  51. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL . Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications . JAMA . 293 . 19 . 2372–2383 . May 2005 . 15900008 . 10.1001/jama.293.19.2372 . 30284439 .
  52. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS, Tondo L, Findling RL, Youngstrom EA, Tohen M, Undurraga J, González-Pinto A, Goldberg JF, Yildiz A, Altshuler LL, Calabrese JR, Mitchell PB, Thase ME, Koukopoulos A, Colom F, Frye MA, Malhi GS, Fountoulakis KN, Vázquez G, Perlis RH, Ketter TA, Cassidy F, Akiskal H, Azorin JM, Valentí M, Mazzei DH, Lafer B, Kato T, Mazzarini L, Martínez-Aran A, Parker G, Souery D, Ozerdem A, McElroy SL, Girardi P, Bauer M, Yatham LN, Zarate CA, Nierenberg AA, Birmaher B, Kanba S, El-Mallakh RS, Serretti A, Rihmer Z, Young AH, Kotzalidis GD, MacQueen GM, Bowden CL, Ghaemi SN, Lopez-Jaramillo C, Rybakowski J, Ha K, Perugi G, Kasper S, Amsterdam JD, Hirschfeld RM, Kapczinski F, Vieta E . The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders . The American Journal of Psychiatry . 170 . 11 . 1249–1262 . November 2013 . 24030475 . 4091043 . 10.1176/appi.ajp.2013.13020185 . free .
  53. Stadlmann S, Portmann S, Tschopp S, Terracciano LM . Venlafaxine-induced cholestatic hepatitis: case report and review of literature . The American Journal of Surgical Pathology . 36 . 11 . 1724–1728 . November 2012 . 23073329 . 10.1097/pas.0b013e31826af296 . Ovid Technologies (Wolters Kluwer Health) .
  54. Book: Baselt R . Disposition of Toxic Drugs and Chemicals in Man . 8th . Biomedical Publications . Foster City, CA . 2008 . 1634–1637 . 978-0-9626523-7-0.
  55. Web site: 2006 . Wyeth Letter to Health Care Providers . Wyeth Pharmaceuticals Inc . 6 August 2009 . 27 August 2009 . https://web.archive.org/web/20090827092615/http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150546.htm . live .
  56. Taylor D, Lenox-Smith A, Bradley A . A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose . Therapeutic Advances in Psychopharmacology . 3 . 3 . 151–161 . June 2013 . 24167687 . 3805457 . 10.1177/2045125312472890 .
  57. Hanekamp BB, Zijlstra JG, Tulleken JE, Ligtenberg JJ, van der Werf TS, Hofstra LS . Serotonin syndrome and rhabdomyolysis in venlafaxine poisoning: a case report . The Netherlands Journal of Medicine . 63 . 8 . 316–318 . September 2005 . 16186642 . 6 November 2013 . live . PDF . https://web.archive.org/web/20160304231924/http://www.njmonline.nl/getpdf.php?id=432 . 4 March 2016 .
  58. Papp A, Onton JA . Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation . The Primary Care Companion for CNS Disorders . 20 . 6 . 18m02311 . December 2018 . 30605268 . 10.4088/PCC.18m02311 . 58577252 .
  59. Rizkalla M, Kowalkowski B, Prozialeck WC . Antidepressant Discontinuation Syndrome: A Common but Underappreciated Clinical Problem . The Journal of the American Osteopathic Association . 120 . 3 . 174–178 . February 2020 . 32077900 . 10.7556/jaoa.2020.030 .
  60. Petit J, Sansone RA . A case of interdose discontinuation symptoms with venlafaxine extended release . The Primary Care Companion for CNS Disorders . 13 . 5 . 2011 . 22295261 . 3267502 . 10.4088/PCC.11l01140 .
  61. Hosenbocus S, Chahal R . SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents . Journal of the Canadian Academy of Child and Adolescent Psychiatry . 20 . 1 . 60–67 . February 2011 . 21286371 . 3024727 .
  62. Haddad PM . Antidepressant discontinuation syndromes . Drug Safety . 24 . 3 . 183–197 . March 2001 . 11347722 . 10.2165/00002018-200124030-00003 . 26897797 .
  63. Campagne DM . Venlafaxine and serious withdrawal symptoms: warning to drivers . MedGenMed . 7 . 3 . 22 . July 2005 . 16369248 . 1681629 .
  64. Web site: Venlafaxine Side Effects in Detail . 3 January 2018 . 3 October 2020 . https://web.archive.org/web/20201003115943/https://www.drugs.com/sfx/venlafaxine-side-effects.html . live .
  65. Khurana RN, Baudendistel TE . Hypertensive crisis associated with venlafaxine . The American Journal of Medicine . 115 . 8 . 676–677 . December 2003 . 14656626 . 10.1016/S0002-9343(03)00472-8 .
  66. Thase ME . Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients . The Journal of Clinical Psychiatry . 59 . 10 . 502–508 . October 1998 . 9818630 . 10.4088/JCP.v59n1002 .
  67. Edvardsson B . Venlafaxine as single therapy associated with hypertensive encephalopathy . SpringerPlus . 4 . 1 . 97 . 26 February 2015 . 25763307 . 4348355 . 10.1186/s40064-015-0883-0 . free .
  68. Johnson EM, Whyte E, Mulsant BH, Pollock BG, Weber E, Begley AE, Reynolds CF . Cardiovascular changes associated with venlafaxine in the treatment of late-life depression . The American Journal of Geriatric Psychiatry . 14 . 9 . 796–802 . September 2006 . 16943176 . 10.1097/01.JGP.0000204328.50105.b3 .
  69. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT . Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors . Neuropsychopharmacology . 25 . 6 . 871–880 . December 2001 . 11750180 . 10.1016/S0893-133X(01)00298-6 . free .
  70. Sabatucci JP, Mahaney PE, Leiter J, Johnston G, Burroughs K, Cosmi S, Zhang Y, Ho D, Deecher DC, Trybulski E . Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors . Bioorganic & Medicinal Chemistry Letters . 20 . 9 . 2809–2812 . May 2010 . 20378347 . 10.1016/j.bmcl.2010.03.059 .
  71. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT . Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors . Neuropsychopharmacology . 25 . 6 . 871–880 . December 2001 . 11750180 . 10.1016/S0893-133X(01)00298-6 . free .
  72. Roth BL, Kroeze WK . Screening the receptorome yields validated molecular targets for drug discovery . Current Pharmaceutical Design . 12 . 14 . 1785–1795 . 2006 . 16712488 . 10.2174/138161206776873680 . Bryan Roth .
  73. Goeringer KE, McIntyre IM, Drummer OH . Postmortem tissue concentrations of venlafaxine . Forensic Science International . 121 . 1–2 . 70–75 . September 2001 . 11516890 . 10.1016/S0379-0738(01)00455-8 .
  74. Web site: venlafaxine . National Cancer Institute . https://web.archive.org/web/20220124090908/https://www.cancer.gov/publications/dictionaries/cancer-drug/def/venlafaxine . 24 January 2022 .
  75. Book: https://www.ncbi.nlm.nih.gov/books/NBK535363/. StatPearls. Venlafaxine. 2022. StatPearls. 30570984 . 24 January 2022. 30 June 2022. https://web.archive.org/web/20220630225510/https://www.ncbi.nlm.nih.gov/books/NBK535363/. live. Singh D, Saadabadi A .
  76. Wellington K, Perry CM . Venlafaxine extended-release: a review of its use in the management of major depression . CNS Drugs . 15 . 8 . 643–669 . 2001 . 11524036 . 10.2165/00023210-200115080-00007 . 26795121 .
  77. Web site: Stahl's Essential Psychopharmacology – Cambridge University Press . Stahlonline.cambridge.org . 21 November 2013 . 27 February 2012 . https://web.archive.org/web/20120227144244/http://stahlonline.cambridge.org/prescribers_drug.jsf?page=0521683505c95_p539-544.html.therapeutics&name=Venlafaxine&title=Therapeutics . live .
  78. Delgado PL, Moreno FA . Role of norepinephrine in depression . The Journal of Clinical Psychiatry . 61 . Suppl 1 . 5–12 . 2000 . 10703757 .
  79. Aldosary F, Norris S, Tremblay P, James JS, Ritchie JC, Blier P . Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder . The International Journal of Neuropsychopharmacology . 25 . 4 . 283–292 . April 2022 . 34958348 . 9017767 . 10.1093/ijnp/pyab086 .
  80. Book: Stern TA, Fava M, Wilens TE, Rosenbaum JF . Massachusetts General Hospital Comprehensive Clinical Psychiatry . 2015 . Elsevier Health Sciences . 978-0-323-29507-9 . 860 . 9 May 2020 . 27 August 2021 . https://web.archive.org/web/20210827181241/https://books.google.com/books?id=deR1BwAAQBAJ&pg=PA860 . live .
  81. Book: The Opioid System as the Interface between the Brain's Cognitive and Motivational Systems . 2018 . Academic Press . 978-0-444-64168-7 . 73 . 9 May 2020 . 27 August 2021 . https://web.archive.org/web/20210827181238/https://books.google.com/books?id=sEFyDwAAQBAJ&pg=PA73 . live .
  82. Pae CU . Desvenlafaxine in the treatment of major depressive disorder . Expert Opinion on Pharmacotherapy . 12 . 18 . 2923–2928 . December 2011 . 22098230 . 10.1517/14656566.2011.636033 . 33558428 .
  83. Shams ME, Arneth B, Hiemke C, Dragicevic A, Müller MJ, Kaiser R, Lackner K, Härtter S . CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine . Journal of Clinical Pharmacy and Therapeutics . 31 . 5 . 493–502 . October 2006 . 16958828 . 10.1111/j.1365-2710.2006.00763.x . 22236102 . free .
  84. Book: Medical Genetics Summaries . Venlafaxine Therapy and CYP2D6 Genotype . https://www.ncbi.nlm.nih.gov/books/NBK305561/ . Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL, Malheiro AJ . 3 . National Center for Biotechnology Information (NCBI) . 2015 . 28520361 . Bookshelf ID: NBK305561 . Dean L . 7 February 2020 . 26 October 2020 . https://web.archive.org/web/20201026145821/https://www.ncbi.nlm.nih.gov/books/NBK61999/ . live .
  85. Parker G, Blennerhassett J . Withdrawal reactions associated with venlafaxine . The Australian and New Zealand Journal of Psychiatry . 32 . 2 . 291–294 . April 1998 . 9588310 . 10.3109/00048679809062742 . 34824025 .
  86. Web site: Rs2032583 -SNPedia . Snpedia.com . 21 November 2013 . 11 December 2013 . https://web.archive.org/web/20131211083916/http://www.snpedia.com/index.php/Rs2032583 . live .
  87. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Pütz B, Binder EB, Müller-Myhsok B, Holsboer F . Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression . Neuron . 57 . 2 . 203–209 . January 2008 . 18215618 . 10.1016/j.neuron.2007.11.017 . 6772775 . free .
  88. Whyte IM, Dawson AH, Buckley NA . Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants . QJM . 96 . 5 . 369–374 . May 2003 . 12702786 . 10.1093/qjmed/hcg062 . free .
  89. DeVane CL . Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea . The Journal of Clinical Psychiatry . 64 . Suppl 18 . 14–19 . 2003 . 14700450 .
  90. Book: 2006 Lippincott's Nursing Drug Guide . registration . Karch A . 2006 . Lippincott Williams & Wilkins . Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo . 978-1-58255-436-5.
  91. Thundiyil JG, Kearney TE, Olson KR . Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System . Journal of Medical Toxicology . 3 . 1 . 15–19 . March 2007 . 18072153 . 3550124 . 10.1007/BF03161033 .
  92. Iliou T, Casta P, Lequeux J, Pochard L, Frauger E, Spadari M, Micallef J . Venlafaxine Abuse in a Patient With a History of Methylphenidate Abuse: A Case Report . Journal of Clinical Psychopharmacology . 39 . 2 . 172–174 . 2019 . 30811375 . 10.1097/JCP.0000000000001011 . 73496502 .
  93. News: Staton T . Drugstores accuse Pfizer, Teva of blocking Effexor generics. FiercePharma. 13 June 2012. 22 June 2017. 26 November 2020. https://web.archive.org/web/20201126124935/https://www.fiercepharma.com/sales-and-marketing/drugstores-accuse-pfizer-teva-of-blocking-effexor-generics. live.
  94. Web site: Venlafaxine. January 2020. Drugs.com. Drugsite Trust. Dallas, Texas. Brand Names. 24 January 2020. 6 September 2020. https://web.archive.org/web/20200906074924/https://www.drugs.com/international/venlafaxine.html. live.
  95. Web site: Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan . Pfizer . Business Wire . 16 November 2020 . 17 June 2024.
  96. Web site: Brands . Viatris . 16 November 2020 . 17 June 2024.
  97. Book: 2 . 2012 . . . Gupta RC . Veterinary Toxicology : Basic and Clinical Principles . 978-0-12-385926-6 . 794491298 . xii+1438.
  98. Chia MA, Lorenzi AS, Ameh I, Dauda S, Cordeiro-Araújo MK, Agee JT, Okpanachi IY, Adesalu AT . Susceptibility of phytoplankton to the increasing presence of active pharmaceutical ingredients (APIs) in the aquatic environment: A review . Aquatic Toxicology . 234 . 105809 . May 2021 . 33780670 . 10.1016/j.aquatox.2021.105809 . . 2021AqTox.23405809C . 232419482 .
  99. Web site: The Top 5 Cat Toxins . 3 May 2023 . Pet Health Network . en.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Venlafaxine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.